本頁面由Tiger Trade Technology Pte. Ltd.提供服務

康乃德生物醫藥

1.10
-0.6250-36.23%
成交量:949.34萬
成交額:1,096.20萬
市值:6,926.02萬
市盈率:-0.92
高:1.30
開:1.28
低:1.06
收:1.73
52周最高:3.82
52周最低:1.06
股本:6,296.39萬
流通股本:2,106.61萬
量比:11.27
換手率:45.06%
股息:- -
股息率:- -
每股收益(TTM):-1.1933
每股收益(LYR):-1.0000
淨資產收益率:-140.51%
總資產收益率:-69.75%
市淨率:2.58
市盈率(LYR):-1.10

資料載入中...

2023/02/13

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/01/03

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/07/01

SEC問詢函

CORRESP [Cover] - Correspondence
2022/07/01

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/06/17

SEC問詢函

CORRESP [Cover] - Correspondence
2022/05/20

SEC問詢函

CORRESP [Cover] - Correspondence
2022/03/31

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/25

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/25

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/15

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/06/07

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/03/29

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/03/19

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/03/18

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/03/17

SEC問詢函

CORRESP [Cover] - Correspondence
2021/03/17

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/03/16

SEC問詢函

CORRESP [Cover] - Correspondence